$70.230
+0.471 (+0.67%)收盤時
GEHC 資訊
GEHC 事件
GE HealthCare Launches Global Clinical Evaluation Program for StarGuide GX
GE HealthCare announced a global clinical evaluation program spanning three continents and five institutions to assess StarGuide GX, its next-generation digital 4D SPECT/CT system. Participating institutions include Hadassah Medical Center in Israel; Mayo Clinic in the United States; Oncopole Claudius Regaud - Institut Universitaire du Cancer de Toulouse in France; Peking University First Hospital in China; and Rambam Health Care Campus. Across the program, participating institutions will evaluate image quality, quantitative performance, dynamic imaging and workflow while providing clinical and research feedback to help inform the future evolution of StarGuide GX, the company said in a statement.
GE HealthCare Launches New LOGIQ Focus Ultrasound System
GE HealthCare announced LOGIQ Focus, a new addition to its LOGIQ family of general imaging ultrasound systems, designed to bring advanced imaging tools to a broader range of ultrasound exams. "As demand for imaging grows, clinicians shouldn't have to choose between image quality and efficiency," said Karley Yoder, Chief Executive Officer, Ultrasound Solutions, Advanced Imaging Solutions, GE HealthCare. "LOGIQ Focus builds on more than 30 years of LOGIQ innovation to deliver both, combining advanced imaging and clinician-centered AI-enabled tools that care teams rely on every day."
GE HealthCare Publishes Anesthesia Study from University of Michigan
GE HealthCare announced the publication of research conducted at the University of Michiganiv evaluating the use of End-tidal Control software across a large multisite academic health system in Anesthesia & Analgesia Practice. The retrospective observational study analyzed 12,818 adult general anesthesia cases performed at University of Michigan Health - Ann Arbor locations between April 1, 2023 and September 30, 2024 on anesthesia machines with End-tidal Control software. The study found End-tidal Control was used in 6,755 cases and its use was associated with: 62.3% reduction in median fresh gas flow during maintenance of anesthesia; 39.3% reduction in sevoflurane consumption. "Health systems are looking for practical ways to support clinicians while advancing more sustainable care," said John Beard, MD, anesthesiologist and Chief Medical Officer of Patient Care Solutions at GE HealthCare. "This research at the University of Michigan adds important real-world evidence of End-tidal Control use at scale and how it may help reduce fresh gas flows and anesthetic agent consumption." End-tidal Control software supports the clinician in maintaining clinician-set targets for end-tidal anesthetic agent and oxygen concentrations with greater accuracy than manual adjustments. End-tidal Control supports low-flow anesthesia, which may help reduce the amount of anesthetic agent utilized and potentially lower greenhouse gas emissions and costs. The study also found variation in End-tidal Control use was significantly driven by the in-room anesthesia clinician, underscoring the importance of workflow, education and implementation considerations when deploying anesthesia technologies at scale.
GE HealthCare Announces MINItrace Magni Achieves CE Mark
GE HealthCare announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 production. The developments reflect the company's focus on helping institutions build the production capabilities behind their molecular imaging programs. Key highlights: MINItrace Magni combines a compact, self-shielded design with automated operation to help healthcare providers establish and expand local production of radioisotopes used in PET tracers; Copper-64 expands the PETtrace Solid Target Platform beyond Gallium-68, supporting research in both copper-based imaging agents and the potential Copper-64/Copper-67 theranostic pair
Nasdaq Rises Nearly 300 Points as Market Digests Jobs Report
The major averages ended broadly higher, led by tech with the Nasdaq up roughly nearly 300 points. The 10-year Treasury yield remains near multiyear highs, but oil prices pulled back to drop below $90 a barrel.The market continues digesting Friday's weaker-than-expected September jobs report, which reduced expectations for another Fed rate hike this month. Traders now see roughly an 80% probability that the Fed holds rates steady in October, although a December hike remains largely priced in.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Schneider Electricagreed to acquire PTCFor $205 per share in cashC.H. Robinsonagreed to acquire RXO Inc.for $30.25 per shareGE Healthcarewill acquire SOFIE Biosciences for $945M in cashTeslaCEO Elon Musk confirmed discussions between his Terafab semiconductor production initiative and TSMCUnitedHealthis under investigation by Texas AG Ken Paxton amid alleged unlawful practices2. WALL STREET CALLS:Melius calls Microsoftthe "adults in charge" of AI, upgrades to BuyDraftKingsupgraded to Buy at BofA following 47% pullbackMorgan Stanley downgraded Group 1 Automotiveto Underweight and AutoNationto Equal WeightWells Fargoupgraded to Overweight at Morgan StanleyCiti upgraded Harley-Davidsonto Buy after several years of caution3. AROUND THE WEB:Despite being two of Anthropic's largest corporate customers, Metaand Microsoftare looking to lower their employees' use of Claude, The Information reportsStarbucksis being sued by customers who claim the company falsely advertised eight protein drinks as "sugar-free" because they contain lactose, Reuters reportsAppleCEO John Ternus has effectively become the company's design chief, working in the studio several times a week, Bloomberg reportsQualcommand Armwill be facing one another in court, with Qualcomm accusing the company of withholding chip testing tools under contract, Reuters saysStablecoin Developmentappears highly speculative and considers the stock uninvestable at any price above zero, Fugazi Research says in a new research note4. MOVERS:Vaxcytegained after announcing "positive" results from OPUS-1 Phase 3 trial of VAX-31Alvotechincreased in New York after the U.S. FDA approved a supplement to the biologics license application for SimlandiUpstartwas higher after reporting originations for September and Q3Millrose Propertiesfell after Citizens downgraded the stock to Market PerformCapricorwas lower after announcing open-label extension data for Deramiocel5. EARNINGS/GUIDANCE:NeuroOne Medicalprovided guidance for Q4 and FY26Insmedbacked its brinsupri outlook for FY26inTESTprovided guidance for Q3Forum Marketsannounced its outlook for FY27Camping Worldexpects its FY26 adjusted EBITDA guidance to be below the low endINDEXES:The Dow rose 90.94, or 0.18%, to 51,267.90, the Nasdaq gained 286.45, or 1.05%, to 27,477.31, and the S&P 500 advanced 51.23, or 0.66%, to 7,773.95.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。